Bisphosphonate use and subsequent prescription of acid suppressants

British Journal of Clinical Pharmacology

Volumn 57, Issue 6, 2004, Pages 813-816

  Roughead, E E ^a   McGeechan, K ^b   Sayer, G P ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Health Communication Network   (Australia)

Author keywords

Adverse drug reactions; Adverse gastrointestinal events; Bisphosphonates

Indexed keywords

ALENDRONIC ACID; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; ETIDRONIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; ESOPHAGITIS; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PAGET BONE DISEASE; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; ANTACIDS; CASE-CONTROL STUDIES; COHORT STUDIES; DIPHOSPHONATES; ESOPHAGEAL DISEASES; FAMILY PRACTICE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROTON PUMPS;

EID: 2942605810     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02078.x     Document Type: Article

References (11)

1. Adverse Drug Reactions Advisory Committee. A gut feeling for alendronate. Aust Adverse Drug Reactions Bulletin 1999; 18: 3.
2. de Groen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-21.
3. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. United Kingdom experience with alendronate and oesophageal reactions. Br J General Pract 1998; 48: 1161-2.
4. Kherani RB, Papaioannou A, Adachi JD. Long term tolerability of the bisphosphonates in postmenopausal osteoporosis. Drug Safety 2002; 25: 781-90.
5. Bauer DC, Black D, Ensrun K et al. Upper gastrointestinal tract safety profile of alendronate. Arch Intern Med 2000; 160: 517-25.
6. Taggart H, Bolognese MA, Lindsay R et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77: 262.
7. Sayer GP, McGeechan K, Kemp A et al. The General Practice Research Network: the capabilities of an electronic patient management system for longitudinal patient data. Pharmacoepidemiol Drug Saf 2003; 12: 483-9.
8. Colebatch KA, Marley J, Doecke C, Miles H, Gilbert A. Evaluation of a patient event report monitoring system. Pharmacoepidemiol Drug Saf 2000; 9: 491-9.
9. Mitchell AS, Henry DA, Hennrikus D, O'Connell DL. Adverse drug reactions: can consumers provide early warning? Pharmacoepidemiol Drug Saf 1994; 3: 257-64.
10. Marx BD, Pallack L, Canchola JA. LOGITSE. A SAS Macro for Logistic Regression Modeling in Complex Surveys. San Francisco: University of California, 1995.
11. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161: 107.